Coculturing antigen-presenting DCs solely with OT-1 cells resulted in strong T cell activation, proliferation, DNA Synthesis inhibitor and expansion, whereas HSCs alone did not

exert any stimulatory function because of their dysfunctional MHC-I molecule expression (Fig. 1A). Importantly, coculturing HSCs together with DCs and OT-1 T cells strongly impaired DC-mediated T cell activation (Fig. 1A). Antigen processing in DCs was not affected by HSCs because HSCs also prevented T cell proliferation by peptide-loaded DCs or DCs presenting endogenous peptides (Supporting Fig. 1). To investigate whether HSCs acted on DCs to impair their APC function or acted directly on T cells to prevent their activation, we replaced DCs with artificial APCs, that is, αCD3/CD28-coated microbeads that directly elicited T cell activation. HSCs also prevented the proliferation and expansion of naive T cells under these conditions (Fig. 1B), and this indicated a direct action on T cells. We confirmed the inhibitory effect on T cell proliferation with the help of the marker Ki-67, which was not up-regulated in cocultures of αCD3/CD28-stimulated T cells with HSCs (Fig. 1C). This veto function of HSCs was not restricted to a particular

genetic background because HSCs from H-2d mice also impaired αCD3/CD28-induced MLN0128 cost T cell proliferation (Supporting Fig. 2). The lack of proliferation was not due to an

increased rate of apoptosis because HSCs did not cause apoptotic T cell death (Fig. 1D). However, the HSC veto function was restricted to naive T cells because the stimulation of already activated T cells was not affected at all by HSCs (Fig. 1E). We extended our study to human cells with the HSC cell line LX-2. Clearly, the veto function for the inhibition of T cell activation was also valid for human HSCs in the presence of human or murine T cells (Fig. 1F and Supporting Fig. 2); this confirms that primary human HSCs also impede the TCR-driven proliferation of human naive CD8+ T cells.22 These results demonstrate the species-independent ability of HSCs to control T cell function. HSCs reduced the up-regulation of the activation markers CD25 und CD44 and medchemexpress inhibited the shedding of CD62L in αCD3/CD28-stimulated T cells (Fig. 2A). However, the activation marker CD69 was similarly up-regulated on T cells in the presence of HSCs (Fig. 2A). The release of cytokines from bead-stimulated T cells was impaired but was not completely suppressed by HSCs (Fig. 2B), and this indicated that T cells underwent an initial activation that was subsequently curtailed by the HSC veto function. Similarly, a phorbol 12-myristate 13-acetate (PMA)/ionomycin treatment, which acted downstream of TCR signaling, did not induce T cell proliferation in the presence of HSCs (Fig. 2C).